Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

December 15, 2017

Primary Completion Date

October 14, 2019

Study Completion Date

October 14, 2019

Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
BIOLOGICAL

Nivolumab

Specified dose on specified day

DRUG

Cetuximab

Specified dose on specified day

DRUG

Cisplatin

Specified dose on specified day

RADIATION

Radiotherapy

Specified dose on specified day

Trial Locations (55)

704

Local Institution, Tainan City

6100

Local Institution, Nice

11042

Monter Cancer Center - Center for Advanced Medicine Location, Lake Success

13005

Local Institution, Marseille

15232

Upmc- Hillman Cancer Center, Pittsburgh

15706

Local Institution, A Coruña

19124

Eastern Regional Medical Center, Philadelphia

22042

Inova Health System, Falls Church

28046

Local Institution, Madrid

28222

Local Institution, Majadahonda

28644

Local Institution, Cheongju-si

28942

Local Institution, Madrid

30265

CTCA Southeastern Region, Newnan

30308

Winship Cancer Insitute, Emory Crawford Long Hospital, Atlanta

31792

Lewis Hall Singletary Oncology Center at John D. Archbold Memorial Hospital, Thomasville

32806

Orlando Health, Inc, Orlando

35000

Local Institution, Izmir

36207

Pinnacle Research Group, Llc, Anniston

38043

Local Institution, Grenoble

40447

Local Institution, Taichung

40705

Local Institution, Taichung

46015

Local Institution, Valencia

46845

Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne

48121

Local Institution, Ravenna

55100

Local Institution, Lucca

58128

Local Institution, Jeollanam-do

60099

Midwestern Regional medical Center, Zion

66205

University of Kansas Cancer Center, Westwood

77030

The University of Texas MD Anderson Cancer Center-merge, Houston

85338

Cancer Treatment Centers of Phoneix, Goodyear

90095

UCLA Health, Los Angeles

90277

Cancer Care - Torrance Memorial Physician Network, Redondo Beach

98310

HHP Hematology & Oncology Bremerton, Bremerton

129515

Local Institution, Moscow

620036

Local Institution, Yekaterinburg

2591193

Local Institution, Isehara

2778577

Local Institution, Kashiwa-shi

3058576

Local Institution, Tsukuba

4648681

Local Institution, Nagoya

5418567

Local Institution, Osaka

5898511

Local Institution, Osaka-sayama-shi

6500017

Local Institution, Kobe

6738558

Local Institution, Akashi-shi

8128582

Local Institution, Fukuoka

85724-5024

University of Arizona Cancer Center, Tucson

06062

Cancer Center of Central Connecticut, Plainville

68114-4108

Nebraska Methodist Hospital, Omaha

77802-2585

St. Joseph Regional Cancer Center, Bryan

791-0280

Local Institution, Matsuyama

981-1293

Local Institution, Natori-shi

113-8519

Local Institution, Bunkyo-ku

81 519

Local Institution, Gdynia

06351

Local Institution, Seoul

06591

Local Institution, Seoul

08003

Local Institution, Barcelona

Sponsors
All Listed Sponsors
collaborator

Ono Pharmaceutical Co. Ltd

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY

NCT03349710 - Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer | Biotech Hunter | Biotech Hunter